Meropenem: a review of its use in patients in intensive care (Q33897244)

29 July 2017

1 reference

title

Meropenem: a review of its use in patients in intensive care (English)

1 reference

29 July 2017

1 reference

ChEBI release 2020-05-28

M Hurst

1

1 reference

29 July 2017

H M Lamb

series ordinal

2

1 reference

29 July 2017

publication date

1 March 2000

1 reference

29 July 2017

1 reference

29 July 2017

volume

59

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

653-680

1 reference

Antimicrobial resistance in developing countries

29 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059030-00016

The postantibiotic effect of meropenem and imipenem on selected bacteria

21 January 2018

1 reference

12 December 2020

Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections

1 reference

12 December 2020

In vitro synergistic activity between meropenem and other beta-lactams against methicillin-resistantStaphylococcus aureus

1 reference

12 December 2020

Pharmacodynamic effects of meropenem on gram-negative bacteria.

1 reference

12 December 2020

The pharmacokinetics of meropenem in volunteers

1 reference

12 December 2020

In-vitro selection of porin-deficient mutants of two strains of Klebsiella pneumoniae with reduced susceptibilities to meropenem, but not to imipenem

1 reference

12 December 2020

Risk reduction in the intensive care unit

1 reference

12 December 2020

Treatment of sepsis: past and future avenues

1 reference

12 December 2020

The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee

1 reference

12 December 2020

Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System.

1 reference

12 December 2020

[Clinical experience with meropenem in the treatment of severe infections in critically ill patients.]

1 reference

12 December 2020

Hydrolysis of imipenem, meropenem, ceftazidime, and cefepime by multiresistant nosocomial strains of Sphingobacterium multivorum

1 reference

12 December 2020

Ventilator-associated pneumonia. A multivariate analysis

1 reference

12 December 2020

Bacterial resistance: a worldwide problem

1 reference

12 December 2020

Approaches to limiting emergence of antimicrobial resistance in bacteria in human populations

1 reference

12 December 2020

Tumor necrosis factor alpha and interleukin 6 release induced by antibiotic killing of Pseudomonas aeruginosa and Staphylococcus aureus

1 reference

12 December 2020

Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria.

1 reference

12 December 2020

Nosocomial infection rates in adult and pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System

1 reference

12 December 2020

Pharmacokinetics of meropenem in subjects with various degrees of renal impairment

1 reference

12 December 2020

Carbapenem resistance in a clinical isolate of Citrobacter freundii

1 reference

12 December 2020

Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.

1 reference

12 December 2020

Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections

1 reference

12 December 2020

Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group

1 reference

12 December 2020

Meropenem in elderly and renally impaired patients

1 reference

12 December 2020

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

1 reference

12 December 2020

Meropenem: in-vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group

1 reference

12 December 2020

Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children. Italian Pediatric Meropenem Study Group

1 reference

12 December 2020

Mechanisms of resistance to beta-lactam antibiotics

1 reference

12 December 2020

Antibiotic resistance caused by gram-negative multidrug efflux pumps

1 reference

12 December 2020

A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections.

1 reference

12 December 2020

Meropenem resistance in Pseudomonas aeruginosa

1 reference

12 December 2020

Laboratory data which differentiate meropenem and imipenem.

1 reference

12 December 2020

Postantibiotic Effect of Carbapenems against Pseudomonas aeruginosa

1 reference

12 December 2020

Guidelines for prevention of nosocomial pneumonia. Centers for Disease Control and Prevention

1 reference

12 December 2020

In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group

1 reference

12 December 2020

Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions

1 reference

12 December 2020

The pharmacokinetics of meropenem in surgical patients with moderate or severe infections

1 reference

12 December 2020

Comparative in vitro activity of meropenem versus other routinely used antimicrobials against 18632 aerobic bacteria tested in 92 German centers

1 reference

12 December 2020

Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections

1 reference

12 December 2020

Pharmacokinetics of meropenem in subjects with renal insufficiency

1 reference

12 December 2020

Enterococci and vancomycin resistance

1 reference

12 December 2020

Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals

1 reference

12 December 2020

Differences in Therapeutic Efficacy among Cell Wall-Active Antibiotics in a Mouse Model of Gram-Negative Sepsis

1 reference

12 December 2020

Carbapenems in clinical practice: a guide to their use in serious infection

1 reference

12 December 2020

Carbapenem-induced endotoxin release in gram-negative bacterial sepsis rat models

1 reference

12 December 2020

The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock

1 reference

12 December 2020

Pharmacokinetics of meropenem in patients with liver disease

1 reference

12 December 2020

Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci.

1 reference

12 December 2020

Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group

1 reference

12 December 2020

Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician

1 reference

12 December 2020

Antibiotic resistance. Control strategies

1 reference

12 December 2020

A compilation of meropenem tissue distribution data

1 reference

12 December 2020

Meropenem: evaluation of a new generation carbapenem

1 reference

12 December 2020

The pharmacokinetics of meropenem.

1 reference

12 December 2020

Risk factors for the spread of antibiotic-resistant bacteria

1 reference

12 December 2020

Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae

1 reference

12 December 2020

Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration

1 reference

12 December 2020

Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment

1 reference

12 December 2020

Efficacy, safety and tolerability of meropenem as empiric antibiotic therapy in hospitalized pediatric patients

1 reference

12 December 2020

[Use of meropenem in the treatment of severe infections in newborns]

1 reference

12 December 2020

Worldwide emergence of carbapenem-resistant Acinetobacter spp

1 reference

12 December 2020

Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy

1 reference

12 December 2020

Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex

1 reference

12 December 2020

Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 beta-lactamase production and loss of an outer membrane protein

1 reference

12 December 2020

Markedly different rates and resistance profiles exhibited by seven commonly used and newer beta-lactams on the selection of resistant variants of Enterobacter cloacae

1 reference

12 December 2020

The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen

1 reference

12 December 2020

Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli

1 reference

12 December 2020

Extended high-level cross-resistance to antipseudomonal antibiotics amongst Pseudomonas aeruginosa isolates in a university hospital.

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of susceptibility to extended-spectrum beta-lactam antibiotics and ciprofloxacin among gram-negative bacilli isolated from intensive care units

1 reference

12 December 2020

Meropenem, a new carbapenem antibiotic.

1 reference

12 December 2020

Host defence (cationic) peptides: what is their future clinical potential?

1 reference

12 December 2020

The MYSTIC (meropenem yearly susceptibility test information collection) programme.

1 reference

12 December 2020

Comparative convulsant potencies of two carbapenem derivatives in C57 and DBA/2 mice

1 reference

12 December 2020

Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.

1 reference

12 December 2020

Carbapenem-induced resistance to beta-lactams in Pseudomonas aeruginosa.

1 reference

12 December 2020

Drug-resistant Streptococcus pneumoniae.

1 reference

12 December 2020

Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem

1 reference

12 December 2020

Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men

1 reference

12 December 2020

Trends in beta-lactam resistance among Enterobacteriaceae.

1 reference

12 December 2020

Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group

1 reference

12 December 2020

Pharmacokinetics of meropenem in patients with intra-abdominal infections

1 reference

12 December 2020

1 reference

12 December 2020

Emergence of a carbapenem-resistant Klebsiella pneumoniae

1 reference

12 December 2020

Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients

1 reference

12 December 2020

A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide

1 reference

12 December 2020

An in-vitro study of carbapenem-induced morphological changes and endotoxin release in clinical isolates of gram-negative bacilli

1 reference

12 December 2020

Comparative in-vitro activity of meropenem against selected pathogens from hospitalized patients in The Netherlands. MASTIN Study Group

1 reference

12 December 2020

Combination effect of meropenem with aminoglycosides and teicoplanin on Pseudomonas and enterococci

1 reference

12 December 2020

Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease

1 reference

12 December 2020

Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects

1 reference

12 December 2020

Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.

1 reference

12 December 2020

Antibiotic-induced release of endotoxin: in-vitro comparison of meropenem and other antibiotics

1 reference

12 December 2020

Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration

1 reference

12 December 2020

Acquired carbapenemases

1 reference

12 December 2020

Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System

1 reference

12 December 2020

In vitro activity of meropenem against organisms causing serious infections in a Singapore hospital

1 reference

12 December 2020

Stability of meropenem and effect of 1 beta-methyl substitution on its stability in the presence of renal dehydropeptidase I

1 reference

12 December 2020

A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes

1 reference

12 December 2020

Acinetobacter spp. isolates with reduced susceptibilities to carbapenems in a UK burns unit

1 reference

12 December 2020

Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam

1 reference

12 December 2020

Comparison of methodologies used in assessing the postantibiotic effect

1 reference

12 December 2020

A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min

1 reference

12 December 2020

Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males

1 reference

12 December 2020

Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children

1 reference

12 December 2020

Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate.

1 reference

12 December 2020

Risk factors and outcome of nosocomial infections: results of a matched case-control study of ICU patients

1 reference

12 December 2020

Meropenem: evidence of lack of proconvulsive tendency in mice

1 reference

12 December 2020

A comparison of the in vitro postantibiotic effect of meropenem and imipenem versus selected enterobacteriaceae and other pathogens

1 reference

12 December 2020

Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem.

1 reference

12 December 2020

The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit

1 reference

12 December 2020

10.2165/00003495-200059030-00016

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1008484215

0 references

1 reference